This study aimed to investigate how Akkermansia muciniphila can implicate type 2 diabetes mellitus and the mechanisms underlying the effects A. muciniphila on type 2 diabetes mellitus. Normal and streptozotocin-induced diabetic Sprague-Dawley rats were orally administered with A. muciniphila and solvent. After 4 weeks of treatment, diabetic rats orally administered with live or pasteurized A. muciniphila exhibited significant increase in the blood concentration of high-density lipoprotein, and decrease in the hepatic glycogen, serum plasminogen activator inhibitor-1, tumor necrosis factor-α, lipopolysaccharide, malondialdehyde and total glucagon-like peptide-1. Moreover, diabetic rats orally administered with A. muciniphila showed significantly increased species alpha diversity and gene function in gut microbes. These results indicated that A. muciniphila can improve liver function, reduce gluco/lipotoxicity, alleviate oxidative stress, suppress inflammation and normalize intestine microbiota of the host animal, thereby ameliorating type 2 diabetes mellitus. Akkermansia muciniphila might be considered as one of the ideal new probiotics used in the management of type 2 diabetes mellitus in future.
INTRODUCTION
Thousands of microbes reside in the gastrointestinal tract, which usually maintain a harmonious coexistence with their host and play an important role in regulating the host's metabolism, immunity and other physiological processes (Cani and Delzenne 2009) . The health-promoting benefits and related underlying mechanism of these intestinal microbes have attracted much scientific attention. Akkermansia muciniphila is an oval-shaped, gram-negative anaerobe, which taxonomically belongs to phylum Verrucomicrobia, and was firstly isolated from a human fecal sample in 2004 (Derrien et al. 2004) . Akkermansia muciniphila is widely distributed in the human intestinal tract, accounting for 1%-4% of the total gut microbes (Collado et al. 2007) . As a mucin-degrading bacterium, A. muciniphila is capable of using intestinal mucin as its sole carbon and nitrogen source (Derrien et al. 2004) , and mucin degradation in turn leads to increased mucin secretion by mucin-producing goblet cells, thereby thickening the mucin layer. Many related studies have found the abundance of A. muciniphila is decreased in obese and type 2 diabetes mellitus (T2DM) patients (Karlsson et al. 2012; Le Chatelier et al. 2013; Ellekilde et al. 2014) .
T2DM is a very common endocrine and metabolic disease with genetic susceptibility. With the development of social economy, changes in lifestyle, and an aging population, morbidity with T2DM shows an increasing annual trend worldwide. The predominant cause of death in diabetic patients is cardiovascular disease (Martin-Timon et al. 2014) . The striking features of T2DM are low-grade inflammation and changed gut bacteria composition. Evidence strongly suggests that chronic lowgrade inflammation promoted by interactions between an individual's gut microbiota and the individual's diet is an important factor underlying T2DM (Cani and Delzenne et al. 2010) . Mounting evidence suggests that the gluco/lipotoxicity, low-grade inflammation, oxidative stress and endoplasmic reticulum stress contribute to β-cell loss and insulin resistance, thus playing a crucial role in T2DM pathogenesis (Eizirik, Miani and Cardozo 2013) . There is also emerging evidence for the role of impaired gut permeability in T2DM (Creely et al. 2007; Ding et al. 2010) . Gut permeability is mainly regulated by structures of the paracellular pathway called tight junctions, which are regulated by zonulin, an established circulating marker of gut permeability (Fasano et al. 1995) . It has been hypothesized that gut bacteria and bacterial endotoxins may disrupt the intestinal barrier resulting in the leakage of toxins, bacterial components or even live bacteria to target organs, which might contribute to the development of T2DM (Daniel et al. 2014) . Moreover, recent studies have shown that daily oral administration with A. muciniphila to HFD-fed mice clearly improves glucose tolerance (Shin et al. 2014) , suggesting its potential active role in T2DM. Therefore, this study investigated the relationship between A. muciniphila and T2DM as well as the mechanisms underlying the effects A. muciniphila on T2DM.
In the present study, A. muciniphila was orally administered to high-fat diet (HFD) fed and streptozotocin-induced diabetic rats and their physiological and immunological parameters were carefully analyzed.
MATERIALS AND METHODS

Culture of A. muciniphila
Akkermansia muciniphila (DSM 22959) was kindly provided by Professor Liu Li (Glycomics and Glycan Bioengineering Research Center, College of Food Science and Technology, Nanjing Agricultural University, China). Akkermansia muciniphila (DSM 22959) was cultured anaerobically for 48 h in brain and heart infusion (Land bridge technology Corp., Beijing, China) broth containing 1 L-cysteine. Cultures were centrifuged for 10 min at 6000 r/min. The supernatant was discarded, and the bacteria were re-suspended in sterile thioglycolate/phosphate-buffered saline (PBS) with 25% (vol/vol) glycerol under anaerobic conditions. The concentration was adjusted to 1 × 10 10 or 1 × 10 8 CFU/ml for oral administration of live A. muciniphila, whereas A. muciniphila at a concentration of 1 × 10 10 CFU/ml was inactivated by pasteurization for 30 min at 70
• C for oral administration of pasteurized A. muciniphila. Bacterial suspensions were stored at −80 • C. The bacterial concentration was determined by plate counting using brain and heart infusion agar (Land bridge technology Corp., Beijing, China). Before administration by oral gavage, stocked cultures were thawed and diluted 10 times with anaerobic sterile PBS.
Animal model and experimental groups
The animal experiment facility and animals used for the present study were officially approved by the Experimental Animal Management Committee of Sichuan Government (Approved number: SYXK2013-011). Male Sprague-Dawley (SD) rats weighing 160-180 g (6-8 weeks old) were purchased from Sichuan Provincial Hospital Animal Facility (Chengdu, China). The rats were housed in groups of no more than five per cage and maintained under controlled conditions of temperature (22 • C) and relative humidity (55%) with a 12:12-h light:dark cycle. All animals were fed adaptively for 1 week, during which they had free access to water and normal chow diet (NCD) containing corn, wheat, expanded soybean meal, alfalfa meal, multivitamins, choline chloride, complex enzyme, phytase, lysine, methionine, threonine, sodium chloride, calcium hydrogen phosphate, minerals and so on. The rats were then randomly divided into two groups fed with NCD or HFD containing 66% NCD, 20% saccharose, 10% lard, 2.5% cholesterol and 1.5% pig bile acid salt, respectively. After 4 weeks of dietary intervention, all rats were fasted for 6 h; subsequently, HFD-fed rats were intraperitoneally (i.p.) injected with a low dose of streptozocin (STZ, 40 mg/kg body weight), whereas the NCD-fed rats were i.p. injected with vehicle buffer only at a dose of 1 ml/kg. STZ was dissolved in citrate buffer (pH 4.4) at a concentration of 40 mg/ml. All animals had free access to food and water after the injection and were continued on their respective diets (NCD or HFD) until the end of the experiment. At 72 h after STZ injection, the rats were fasted for 6 h and their blood glucose levels were measured using a portable glucometer (ACCU-CHEK R , Basel, Switzerland) by cutting-tail method. Rats with fasting blood glucose (FBG) levels of ≥16.7 mmol/L were considered as diabetic (Wu et al. 2014) .
NCD-fed normal rats were randomly divided into two groups: (i) normal control group (NC), in which rats were treated daily with 0.5 ml sterile PBS containing 2.5% glycerol by oral gavage; and (ii) normal high-dose group (NH), in which rats were orally administrated daily with live A. muciniphila (5 × 10 8/ 0.5 ml). HFDfed diabetic rats were randomly divided into five groups: (i) diabetic control group (DC), in which rats were treated similar to the NC group; (ii) diabetic high-dose group (DH), in which rats were treated similar to the NH group; (iii) diabetic lowdose group (DL), in which rats were treated daily with live A. muciniphila (5 × 10 6 /0.5 ml) by oral gavage; (iv) diabetic pasteurization group (DP), in which rats were treated daily with pasteurized A. muciniphila (5 × 10 8 /0.5 ml) by oral gavage; and (v) diabetic metformin group (DM), where rats were orally administered 200 mg/kg/day of metformin. Oral administrations in each group were performed for 4 weeks. A total of 105 rats were randomly divided into each group according to their weight with 15 rats per group at the beginning of the experiment. Then the number of rats in each group was adjusted due to the failure or lethality of modeling and the difficulty of gavage. After 4 weeks of oral administrations, 77 rats finally survived. Blood samples were collected on the day of sacrifice for analyzing lipometabolism-related parameters, inflammatory cytokines, antioxidant factors, and energy metabolism-related gut hormones. Rats were fasted for 6 h and anesthetized by injecting with 1% pelltobarbitalum natricum dissolved in ddH 2 O at a dosage of 40 mg/kg body weight. Blood was collected from the inferior vena cava using a vacuum and centrifuged at 3000 r/min for 10 min at 4
Sample collection
• C. Serum was collected and stored at −80
• C until further analysis. The rats were anesthetized as discussed above. The abdomen was opened to cut off the left liver lobe. A portion of liver was weighed and placed in a strainer containing 1 ml normal saline for tissue homogenization using a grinding rod. The liver was collected on the day of sacrifice for determining hepatic glycogen content. Liver homogenization was collected and stored at −80
• C until further analysis.
Hepatic glycogen detection
The detection of hepatic glycogen content in the liver tissue homogenate was performed using a rat glycogen enzyme-linked immunosorbent assay (ELISA) kit (DongGe, Beijing, China) according to the manufacturer's instructions and expressed as the total hepatic glycogen content multiplied by the weight of the liver.
FBG and oral glucose tolerance test
FBG was measured 1 day before intervention diets, 72 h after STZ injection, and 4 weeks after oral administration. The rats were fasted from 9:00 AM to 3:00 PM, and blood was collected from the tail vein. Blood glucose was determined using a portable glucometer (ACCU-CHEK R ). Oral glucose tolerance test (OGTT) was performed the day before sacrifice to assess the blood glucose response. Following 6 h of food deprivation, baseline blood was sampled via the tail vein, followed by an oral gavage of 25% glucose solution dissolved in ddH 2 O at a dose of 2 g/kg body weight. At 30, 60, 90, and 120 min after gavage, additional blood samples were taken, and glucose level was immediately measured using a portable glucometer.
Serum analyses
(i) Detection of insulin and plasminogen activator inhibitor-1 (PAI-1): fasting serum levels of insulin and PAI-1 were determined using ELISA kits (DongGe). (ii) Measurement of lipid metabolism-related parameters: fasting serum levels of triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL-C), and low-density lipoprotein (LDL-C) were quantified using assay kits (Nanjing Jiancheng, Nanjing, China). (iii) Measurement of gastrointestinal hormones: fasting serum level of peptide YY (PYY) was determined using ELISA kits (DongGe), while the level of total glucagon-like peptide-1 (total GLP-1) was determined using assay kits (Nanjing Jiancheng). (iv) Measurement of inflammatory markers: fasting serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), lipopolysaccharide (LPS) and Creaction protein (CRP) were quantified using ELISA kits (DongGe). (v) Measurement of antioxidant factors: fasting serum levels of glutathione (GSH), superoxide dismutase (SOD), nitric oxide (NO) and malondialdehyde (MDA) were measured using assay kits (Nanjing Jiancheng).
Measurement of body composition indices
The body weights of rats were recorded 1 day before intervention diets, 1 day before STZ injection, 72 h after STZ injection and weekly during oral administrations. Body composition (fat mass, lean mass, total water and free water) values were evaluated using quantitative nuclear MRI (EchoMRI 3-in-1 Analyzer; EchoMRI, Houston, TX) 1 day before sacrifice and were expressed as a percentage (%) divided by their weight.
Quantitative real-time PCR for A. muciniphila in feces
The amount of 16S ribosomal DNA genes of A. muciniphila was estimated by real-time fluorescence quantitative PCR. DNA samples extracted from feces collected 1 month before STZ injection, 72 h after STZ injection and 4 weeks after oral administrations were quantitatively analyzed using two specific primers: AM1 (5 -CAGCACGTGAAGGTGGGGAC-3 ) and AM2 (5 -CCTTGCGGTTGGCTTCAGAT-3 ), as described by Collado et al. (Collado et al. 2007 ). The amplification reactions were performed in a total volume of 20 μl, containing 2 μl of DNA sample, 10 μl of Ultra SYBR Mixture (CWBIO, Beijing, China) and 0.5 μM each primer. The assays were performed using the CFX96 real-time PCR instrument (Bio-Rad, Hercules, CA) in a protocol comprised of 10 min at 95
• C and 15 s at 95 The data were analyzed using Bio-Rad CFX Manager software (version 1.5) for absolute quantities and normalized by log10 transformation before statistical analysis. The absolute abundance of 16S rDNA genes of A. muciniphila in the fecal samples was calculated by comparing the Ct (cycle threshold) values obtained from standard curves created using serial 10-fold dilutions of pure culture DNA corresponding to 10 2 -10 7 CFU/ml.
Metagenome sequencing of gut microbiota
After 4 weeks of oral administrations, 35 genomic DNA samples (five for each group) were picked randomly for high-throughput metagenome sequencing of the 16S rDNA gene, targeting the V3-V4 hypervariable regions. Metagenome sequencing was performed by Sangon Biotech Corporation (Shanghai, China). The DNA samples were evaluated by agarose gel electrophoresis for integrity detection and then accurately quantified using the Qubit2.0 DNA detection kit (Life Technologies Corp., Carlsbad, CA) for following amplifications. The first PCR was performed using the specific primers 341F (5 -CCCTACACGACGCTCTTCCGATCTGCCTACGGGNGGCWGCAG-3 ) and 805R (5 -GACTGGAGTTCCTTGGCACCCGAGAATTCCAGACT ACHVGGGTATCTAATCC-3 ), thereby integrating the V3-V4 universal primers of the MiSeq platform. The next PCR was performed using Illumina bridge PCR-compatible primers (not provided). The acquired PCR products were purified by the magnetite bead adsorption method (Agencourt AMPure XP, Beckman, USA), and then quantified again to obtain a final DNA concentration of 20 pmol for sequencing.
Statistical analysis
Results are presented as means with their standard errors. Statistical analysis was performed by one-way analysis of variance (ANOVA), followed by Dunnett tests using SPSS 21.0 software (SPSS Inc., Chicago, IL, USA). Due to non-normal distribution, microbial data are expressed as medians with interquartile ranges and compared using the non-parametric Mann-Whitney U test. P values of <0.05 were considered statistically significant for all tests.
RESULTS
Glucose parameters and hepatic glycogen
Based on the result of FBG measured 1 day before intervention diets, the rats were assigned to two groups to receive intervention diets comprising NCD and HFD. After 1 month of intervention diets, the rats received STZ injections, and FBG was measured after 72 h. The results of FBG differed between the NCD and HFD/STZ groups (P < 0.001), with the HFD/STZ groups (24.11 ± 0.5558 mmol/L) having higher glucose levels than the NCD groups (6.139 ± 0.09951 mmol/L). After 4 weeks of oral administrations, FBG differed from the NC and DC groups (P < 0.001). Although no significant difference was observed among the NCD groups (P > 0.05), the DM group had lower glucose values than DC group in the HFD/STZ groups (P < 0.01), indicating that diabetic rats treated with metformin had reduced glucose levels. However, normal rats orally administrated with live A. muciniphila and diabetic rats treated with other oral administrations, except metformin, showed no difference in glucose levels.
OGTT was performed the day before sacrificing the rats and showed a difference between the NCD and HFD/STZ groups; the NCD groups showed more gentle fluctuations and lower peak values than the HFD/STZ groups [P < 0.001 (t = 0, 30, 60, 90, 120)]. No significant difference was observed between the NC and NH groups. In the HFD/STZ groups, only the DM group had lower initial peak values than the DC group [P < 0.05 (t = 30), P < 0.05 (t = 60)], but clearance was not significantly different between these two group [P > 0.05 (t = 90), P > 0.05 (t = 120)] (Fig. 1) .
The total hepatic glycogen levels showed no significant difference between the NC and NH groups, indicating that Total hepatic glycogen levels of each group after 4 weeks' treatment. Data were compared using ANOVA following by Dunnett tests to test the difference between the DC group and other groups. Significant difference is marked as follows: * = P < 0.05, * * = P < 0.01, * * * = P < 0.001. Data were presented as means with their SE and compared using ANOVA following by Dunnett tests to test the difference between the DC group and other groups. Significant difference is marked as follows: * = P < 0.05, * * = P < 0.01, * * * = P < 0.001.
normal rats orally administered with A. muciniphila had little influence on the hepatic glycogen level. However, compared with the DC group, the NC, DH, DL, DP and DM groups had significantly lower hepatic glycogen levels (Fig. 2) . Moreover, the surplus hepatic glycogen generated in diabetic rats seemed to be reduced through oral administration with high-dose live A. muciniphila, low-dose A. muciniphila, pasteurized A. muciniphila or metformin.
Glucose and lipid metabolism-related parameters
Serum levels of TG, TC, HDL-C and LDL-C in the DC group tended to be higher but were not significantly different from those in the NC group. Compared with the DC group, the DP and DM groups had significantly higher serum TG levels, the DM group had significantly higher serum TC levels, and the DH, DL, DP and DM groups had significantly higher serum HDL-C levels. Serum LDL-C levels in all non-control groups showed no significant difference when compared with those in the control groups (Table 1) .
Insulin and PAI-1
Fasting serum insulin levels were not significantly different between the NC and DC groups, which indicates that diabetic rats induced by HFD/STZ showed little effects in the secretion of fasting insulin (P > 0.05). The serum PAI-1 levels in the DC group showed no significant difference from those in the NC group but tended to be significantly higher than those in the DL, DP and DM groups (Fig. 3) .
Body composition indices
In the first month of intervention diets, no significant difference was observed between the NCD and HFD groups in weight Figure 3 . The serum PAI-1 levels of each group after 4 weeks' treatment. Data were compared using ANOVA following by Dunnett tests to test the difference between the DC group and other groups. Significant difference is marked as follows: * = P < 0.05, * * = P < 0.01, * * * = P < 0.001.
[P > 0.05 (t = 1), P > 0.05 (t = 2)], which was probably because 1 month of dietary intervention was not long enough or HFD rats ate less than normal diet rats. After STZ injection, the body weights differed between the NCD and HFD/STZ groups, with the HFD/STZ groups showing lower and more stable weights than the NCD groups [P < 0.05 (t = 3), P < 0.001 (t = 4-7)], indicating that diabetic rats lost their weight at the beginning of STZ injection and maintained a stable weight with age. After 4 weeks of oral administrations, no significant difference was observed between the DC group and other HFD/STZ groups, namely DH, DL, DP and DM (Fig. 4) , indicating that diabetic rats treated with oral administrations of the test bacterium showed no difference in weight loss. Levels of lean mass and total water in the DC group tended to be higher but were not significantly different from those in the NC group. Levels of fat mass in the DC group tended to be lower but were not significantly different from those in the NC group. Levels of free water in the DC group were significantly higher than those in the NC group, but no significant difference was observed between the DC and other HFD/STZ groups or between the NC and NH groups in the levels of any of the body composition indices mentioned above, indicating that HFD/STZ could hardly change the body composition of diabetic and normal rats (Table 2) .
Gastrointestinal hormones
Compared with the NC group, the NH group showed no significant difference in any gastrointestinal hormone analyzed (all P > 0.05). Serum levels of PYY in all non-control groups showed no significant difference when compared with those in the control groups (P > 0.05). Compared with the DC group, the NC, DL, DP and DM groups showed significantly lower serum levels of total GLP-1, an inducer of insulin secretion (Fig. 5) .
Inflammatory markers
No significant difference was observed between the NC and NH groups in blood serum levels of TNF-α, LPS, CRP, IL-1β and IL-6. Compared with the DC group, the NC group showed significantly different blood serum levels of CRP and IL-1β. Such influences could not be eliminated by oral administration because no significant difference was observed between the DC and other HFD/STZ groups. Compared with the DC group, all other HFD/STZ groups had significantly lower serum levels of TNF-α. Compared with the DC group, the DL, DP and DM groups had significantly lower serum levels of LPS. Serum levels of IL-6 in all non-control groups showed no significant difference when compared with those in the control groups (Table 3) .
Antioxidant factors
Serum levels of SOD, NO and GSH in all non-control groups showed no significant differences when compared with those in the control groups. Levels of MDA, an intermediate product of lipid oxidation, were significantly higher in the DC group than in the NC group. Further, the levels of MDA were significantly lower in the DL, DP and DM groups than in the DC group. Diabetic rats orally administered with high-dose live A. muciniphila tended to produce lower levels of MDA, but these levels were not significantly different when compared with those in the DC group (Table 4 ). Data were presented as means with their SE and compared using ANOVA following by Dunnett tests to test the difference between the DC group and other groups. Significant difference is marked as follows: * = P < 0.05, * * = P < 0.01, * * * = P < 0.001.
Analysis of A. muciniphila in feces
The concentration of A. muciniphila in feces varied over time as showed in Fig. 6 . The qPCR results for A. muciniphila in feces revealed that microbial communities were strongly determined by the host's disease state because the HFD/STZ (after 72 h) groups showed significantly higher abundance in A. muciniphila than in the NC group. However, this phenomenon varied in the individuals because a significant difference was observed between the DC group and some of the HFD/STZ (after 72 h) groups. Moreover, this phenomenon was hardly changed by oral administration because after 4 weeks of oral administration, no difference was observed between the DC group and the DH, DL, DP and DM groups (Table 5) . From the point of time span, the abundance of A. muciniphila in the NC and NH groups decreased significantly from the age of 6-8 weeks to 10-12 weeks and stayed stable over the next 4 weeks, indicating that oral administration with live A. muciniphila could have little effect on its colonization in the rat gut. In diabetic rats, the abundance of A. muciniphila increased significantly from the age of 6-8 weeks to 10-12 weeks and declined over the next 4 weeks in the DC and DH groups, indicating that the sharp increase in A. muciniphila caused by the diabetic state decreased gradually with age (Table 5) .
Metagenome sequencing of gut microbiota
The sequence reads obtained were analyzed from species alpha diversity based on Bergey's taxonomy after removing nonspecific amplifications. Species alpha diversity is composed of community richness calculated by the ACE index (Fig. 7A) , and community diversity calculated by the Shannon index (Fig. 7B) . Compared with the NC group, the NH group showed no significant change in species alpha diversity. Compared with the NC group, the DC group showed significantly smaller ACE index and Figure 5 . The serum GLP-1 levels of each group after 4 weeks' treatment. Data were compared using ANOVA following by Dunnett tests to test the difference between the DC group and other groups. Significant difference is marked as follows: * = P < 0.05, * * = P < 0.01, * * * = P < 0.001. Data were presented as means with their SE and compared using ANOVA following by Dunnett tests to test the difference between the DC group and other groups. Significant difference is marked as follows: * = P < 0.05, * * = P < 0.01, * * * = P < 0.001. Data were presented as means with their SE and compared using ANOVA following by Dunnett tests to test the difference between the DC group and other groups. Significant difference is marked as follows: * = P < 0.05, * * = P < 0.01, * * * = P < 0.001.
Shannon index. Compared with the DC group, the DH, DL and DP groups tended to show higher ACE index and Shannon index, but these differences were not significant (Table 6 ). The taxonomy data showed that there were two dominant phyla, namely Bacteroidetes and Firmicutes, in the gut microbiome of both the normal and diabetic SD rats. At the phylum level, when compared with the NC group, the DC group had a higher proportion of Bacteroidetes and a lower proportion of Firmicutes and Proteobacteria, but these differences were not significant. Meanwhile, compared with the NC group, the DC group had a Microbial data are presented as medians with interquartile ranges and compared by non-parametric Mann-Whitney U test. Significant difference is marked as follows: * = P < 0.05, * * = P < 0.01, * * * = P < 0.001.
higher proportion of Verrucomicrobia and a lower proportion of Candidatus Saccharibacteria. Compared with the DC group, the DM group had a significantly higher proportion of Verrucomicrobia and the DH group had a significantly higher proportion of Actinobacteria (Table 6) . At the genus level, when compared with the NC group, the DC group had significantly higher proportions of Lactobacillus, Faecalibacterium, Parabacteroides, Parasutterella, Bifidobacterium, Sutterella and Desulfomicrobium (P < 0.05) and significantly lower proportions of Clostridium IV, Anaerostipes, Flavonifractor, Lachnospiracea incertae sedis (above P < 0.05), Clostridium XlVa, Intestinimonas, Alloprevotella, Tannerella (above P < 0.001), and 15 other genera (not shown). Compared with the NC group, the NH group showed no significant difference in abundance of Akkermansia (P > 0.05). Although the DC group tended to have a higher proportion of Akkermansia, the difference was not significant (P > 0.05). Compared with the DC group, the DH and DP groups tended to have higher proportions of Akkermansia, but these differences were not significant (P > 0.05). The DM group had a significantly higher proportion of Akkermansia (P < 0.05). Oral administration made the relative difference in taxonomy composition between diabetic and normal rats relatively smaller, which was in accordance with the result that the similarities of the DL, DP and DM groups were closer to the NC group rather than to the DC group ( Fig. 7C and D) . PICRUSt analysis based on the KEGG database was performed to predict the composition of functional genes. Compared with the DC group, the NC, DH, DL, DP and DM groups had a relatively higher but not significant (P > 0.05) frequency of total functional genes (Fig. 7E) . In different functional categories, the DM group has significantly higher frequency of genes related to cancers, Figure 7 . The metagenome sequencing of gut microbiota analyzed. The horizontal axis representing 1-7 groups means the group of NC, NH, DC, DH, DL, DP and DM orderly. ACE index (A) and Shannon index (B) positively related with community diversity of gut microbiota are showed as box plots. Every box represents the mean with standard deviation of every group. The narrowness of box means less dispersion of samples within group. Taxonomy composition of gut microbiota in the level of phylum (C) and genus (D) is presented as histogram combined with clustering tree based on Bray-Curtis. (E) PICRUSt analysis based on KEGG database was performed to predict the composition of functional genes. endocrine system, folding, sorting and degradation, glycan biosynthesis and metabolism, immune system, metabolism of terpenoids and polyketides, nervous system, neurodegenerative diseases and to transport and catabolism than the DC group (P < 0.05). The DP group has significantly higher frequency of genes related to transport and catabolism than the DC group (P < 0.05). The DH group has significantly higher frequency of genes related to cardiovascular diseases than the DC group (P < 0.05).
DISCUSSION
Gluco/lipotoxicity
Hepatic glycogen plays a key role in blood glucose regulation. It is known that liver cells transform blood glucose into hepatic glycogen after meals, and hepatic glycogen is broken down and converted again to glucose when in the need of energy. Diabetes shifts this balance. In diabetic conditions, lipid metabolism is usually abnormal, with a higher level of plasma TG, TC and LDL-C and a lower level of plasma HDL-C (Kumar et al. 2013) . Elevated levels of TG, TC and LDL-C are considered as risk factors for CVDs, such as coronary heart disease (Ktari et al. 2013; Akindele et al. 2015; Moodley et al. 2015; Rangika, Dayananda and Peiris 2015; Emordi et al. 2016) . Conversely, HDL-C plays a key role in reducing the risk of cardiovascular disease by transporting cholesterol from the periphery to the liver (Xiong et al. 2013; Weng et al. 2014; Moodley et al. 2015) . Our results showed that STZ-diabetic rats had significantly higher levels of hepatic glycogen and slightly more active lipid metabolism than normal rats. After orally administering STZ-diabetic rats with A. muciniphila, hepatic glycogen levels were reduced, whereas HDL-C levels were elevated. These results indicated that A. muciniphila can enhance the ability of resistance to gluco/lipotoxicity.
Inflammatory markers
LPS is a potent inducer of systemic inflammation, which could explain the lower level of host-derived inflammatory mediators (Cani et al. 2007) . T2DM is related to the permeability of gut barrier and consequent leakage of LPS into circulation due to the disruption of multilayered mucus structures and tight junctions in the gut ). The transport of LPS by enterocytederived chylomicrons also leads to an increased serum level LPS (Ghoshal et al. 2009 ). An elevated level of LPS suggests increased gut permeability which is mainly associated with inflammatory bowel disease (Marshall et al. 2004 ). An elevated level of TNF-α, an important inflammatory marker, plays a role in inhibiting the phosphorylation of IRS-1 and Akt substrate 160 in the insulin-signaling cascade, ultimately inducing insulin resistance (Ibfelt et al. 2014; Smitka and Maresova et al. 2015) . Dietinduced changes in the gut microbiota are related to intestinal barrier function, such as HFD increasing gut permeability in animal model, with chronic low-grade inflammation leading to glucose intolerance and insulin resistance (Kim et al. 2012; Geurts et al. 2014) . Furthermore, administration with live A. muciniphila to HFD mice could reduce inflammatory markers and insulin resistance (Everard et al. 2013) . In the present study, normal rats orally administered with live A. muciniphila showed no significant effect in systemic inflammation. Although diabetic rats orally administered with high-dose live A. muciniphila, low-dose live A. muciniphila, pasteurized A. muciniphila, and metformin showed significant effects in systemic inflammation with reduced inflammatory markers of LPS and TNF-α. These data indicated that A. muciniphila might selectively promote the growth of some beneficial bacteria and alleviate systemic inflammation. Moreover, a reduced level of LPS in diabetic rats orally administered with A. muciniphila indicated the capacity of A. muciniphila in decreasing gut permeability. However, in this study, glucose intolerance or insulin resistance in rats was not significantly improved, probably due to the severity of diabetes.
Oxidative stress
It has been reported that increased oxidative stress, impaired antioxidant defense system or increased generation of free radicals, are widely accepted participants in the development of diabetes mellitus (Preetha, Devi and Rajamohan 2012; Adefegha et al. 2014; Liu et al. 2014; Pan et al. 2014) . MDA, a key indicator of free radical-induced lipid peroxidation, is a late-stage lipid oxidation byproduct (Cheng, Liang and Li 2013) . The MDA level increases in the renal cortex, plasma, mesangial cells, and proximal tubule cells under oxidative stress conditions (Niedowicz and Daleke 2005) . In our study, diabetic rats could produce more MDA than normal rats, and the surplus MDA could be reduced through oral administration of low-dose live A. muciniphila, pasteurized A. muciniphila or metformin. This result indicated the capacity of A. muciniphila in fighting against diabetic oxidative damage.
PAI-1
Diabetes is also characterized by increased expression of PAI-1, the principal inhibitor of fibrinolysis (Alessi and JuhanVague et al. 2006 ). Increased PAI-1 levels were detected in patients with CVD, diabetes, obesity, cancer and inflammation (Cesari, Pahor and Incalzi 2010). PAI-1 overexpression inhibits the activation of plasminogen, leading to the downregulation of fibrinolysis, thus maintaining a hypercoagulated state during diabetes. Consequently, hyperinsulinemia-induced impairment of fibrinolysis and hyperglycemia-induced increase in coagulation are predominantly mediated by PAI-1 overexpression (Stegenga et al. 2006) . Elevation of the PAI-1 level in STZ-diabetic mice was associated with an increase of TNF-α (Zhang et al. 2011) . Our study demonstrated that decreased PAI-1 in STZ-diabetic rats orally administered with A. muciniphila was accompanied by a decrease in TNF-α. This indicates the downregulation ability of A. muciniphila in fibrinolysis.
Total GLP-1
The term 'enteroinsular axis' that regulates blood glucose homeostasis refers to the signaling pathways between pancreatic islets and the gut, which is associated with T2DM pathogenesis (Miyawaki et al. 1999; Meier 2009 ). GLP-1, a polypeptide secreted from intestinal L-cells, plays a role in lowering blood glucose, inhibiting β-cell apoptosis and stimulating β-cell replication, neogenesis and differentiation via the enteroinsular axis (Holst et al. 2016) . In our study, diabetic rats could secrete more total GLP-1 than normal rats, and the surplus GLP-1 could be reduced through oral administration with low-dose live A. muciniphila, pasteurized A. muciniphila, or metformin. Our results indicated that A. muciniphila might have the ability to modify intestinal total GLP-1, thus reducing the risk of insulin resistance.
Gut microbiota composition
It is widely accepted that the composition of gut microbiota is established and influenced by both host genetics and environment factors. In turn, gut microbiota bring feedback regulation to host health conditions, such as insulin sensitivity, blood glucose and body weight (Spor, Koren and Ley 2011) . HFD and high-fat, highsugar diets have been repeatedly shown to increase the proportion of Firmicutes to Bacteroidetes (Carmody et al. 2015) , a microbial community structure that is sufficient to induce increased host body fat upon transplantation into germ-free mouse recipients (Turnbaugh et al. 2008; Liou et al. 2013) . Recently, studies on the roles of gastromicrobiota in T2DM have demonstrated that a moderate dysbiosis leads to an increased risk of 'functional dysbiosis' rather than the direct association of a specific microbial species with T2DM pathophysiology (Qin et al. 2012 ). In our study, orally administered live A. muciniphila had little influence on the species alpha diversity of normal rat gut microbiota. In addition, this species alpha diversity decreased under diabetic conditions. Such loss in the community richness and gut microbiota diversity in rats might be moderately recovered by orally administered live or pasteurized A. muciniphila.
Our taxonomy data showed that when diabetes occurred the taxonomy composition was changed at the phylum level without significantly higher proportions of Bacteroidetes, without significantly lower proportions of Firmicutes and Proteobacteria, but with significantly higher proportions of Verrucomicrobia and significantly lower proportions of Candidatus Saccharibacteria. After 4 weeks of oral administration with metformin, the proportion of Verrucomicrobia in the rats' guts increased. In addition, the proportion of Actinobacteria in the rats' gut microbiota increased when orally administered with high-dose live A. muciniphila. At the genus level of Akkermansia, normal rats fed with A. muciniphila had no influence on the proportion of Akkermansia in their gut microbiota. When diabetes occurred, the abundance of Akkermansia increased slightly and continued increasing after 4 weeks of oral administration with live or pasteurized A. muciniphila or metformin. At the same time, the composition of gut microbiota in HFD/STZ rats orally administered with live or pasteurized A. muciniphila or metformin presented greater similarity to normal rats than before.
In our study, the abundance of all functional genes decreased upon the occurrence of diabetes, indicating the increased risk of 'functional dysbiosis'. Such loss in the abundance of functional genes could be moderately recovered by orally administered low-dose live A. muciniphila, pasteurized A. muciniphila or metformin displaying the resistance capacity of A. muciniphila against 'functional dysbiosis'. Finally, our results suggested that the pasteurized A. muciniphila appeared to be more effective than the live A. muciniphila, while low dose of live A. muciniphila appeared to be more effective than the high dose at counteracting the effects of HFD-Streptozotocin treatment. Why and how pasteurization enhances the effects of A. muciniphila remains to be elucidated. Based on Plovier's study, it's probably related to the outer membrane protein Amuc 1100 * which is stable at 70
• C suggesting that pasteurization enhances the effects of A. muciniphila by increasing accessibility of Amuc 1100 * to the host (Plovier et al. 2017) . Regardless, pasteurization might represent an innovative way to improve therapeutic effect. In addition, we hypothesize that the therapeutic effect of live A. muciniphila on HFDStreptozotocin treatment needs a proper dose range. How low dose enhances the effects of live A. muciniphila remains to be elucidated. And the best dose of live A. muciniphila remains to be tested.
